Articles tagged with Meningioma
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
The MOMENTUM-1 study is a phase II trial testing the radioactive drug [177Lu]Lu-DOTA-TATE in adult patients with progressive intracranial grade 1-3 meningioma. The study aims to determine if treatment with [177Lu]Lu-DOTATate improves progression-free survival compared to standard medical therapy.
A new study identifies a genetic biomarker, telomerase reverse transcriptase (TERT), that can predict the aggressiveness of meningiomas. High TERT expression is linked to faster disease progression and poorer outcomes, even in low-grade tumors.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Researchers found that 2.7% of 70-year-old women had meningiomas, a type of tumor on the meninges outside the brain tissue. The study emphasizes the importance of diligence and careful consideration in managing these tumors, which are often benign and grow slowly.
A study found that prolonged use of desogestrel pill is associated with a small increased risk of developing an intracranial meningioma, typically non-cancerous brain tumours. The risk is low compared to other progestogens and disappears one year after stopping treatment.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
This study evaluated the long-term outcomes of gamma knife radiosurgery (GKRS) in patients with grade 2 meningiomas. GKRS was found to be a reasonable treatment option, but higher margin doses were associated with improved local control rates.
A comprehensive review published in Brain Medicine maps out the extensive influence of reproductive hormones on neurological health and disease. The study examines how sex hormones affect a broad spectrum of neurological conditions, including vascular disorders, movement disorders, epilepsy, multiple sclerosis, and Alzheimer's disease.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
Researchers found that intraarterial peptide receptor radionuclide therapy is safe and effective for patients with advanced meningioma, offering improved radiologic and clinical disease control compared to intravenous PRRT. The treatment was well-tolerated, with no additional toxicity, and showed promising results in disease control.
A study published in Science Advances has identified key characteristics of multiply recurrent meningiomas (MRMs), a highly aggressive form of brain tumor. Researchers found that MRMs are more numerous, larger and more common in men than women, with increased chromosomal instability and DNA methylation.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Researchers have developed a minimally invasive surgical technique to remove lesions in the skull base region, reducing damage to the brain and preserving neurological functions. The endoscopic approach results in shorter operative times and less blood loss compared to conventional microscopic surgery.
Researchers from Mass General Cancer Center are set to present key findings on palliative care delivery via telehealth versus in-person for patients with advanced lung cancer. The presentations also cover advances in colorectal and breast cancer treatments, as well as results from a phase 1b/2 study on a novel BRAF inhibitor.
A French study found prolonged use of certain progestogen hormone drugs is associated with an increased risk of developing intracranial meningioma. Medrogestone and medroxyprogesterone acetate were linked to a significant increase in risk, particularly among women using these medications for extended periods.
Recent advances in permeating the brain-blood barrier hold promise for using radiopharmaceuticals to treat brain tumors. Theranostic approaches show encouraging preliminary results, particularly for meningiomas and pediatric brain tumors.
Researchers found that single copy loss of CDKNA/B genes accelerates aggressive meningioma recurrence and offers a poor prognosis. The study suggests refining diagnosis by identifying group C tumors and further checking for CDKN2A/B gene loss.
A study of 184 grade I and II meningiomas found associations between specific tumor mutations and increased or decreased recurrence rates. Mutations in ATM and CREBBP were linked to accelerated recurrence, while POLE mutations showed protective effects, highlighting potential targets for intervention.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
A novel somatostatin-receptor targeting peptide has shown excellent imaging in patients with meningiomas, identifying previously undetected lesions. The new agent offers significant logistical advantages, including a longer half-life and large-scale production capabilities.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
A team of researchers at Baylor College of Medicine has developed a new approach to classify meningiomas into three biologically distinct groups, one of which is reliably malignant. This classification system, which integrates multiple molecular profiling approaches, provides better prognosis and reveals tumors that require more aggres...
Researchers have discovered that HIV drugs may be effective in treating low-grade brain tumours, specifically meningioma and acoustic neuroma. High levels of HERV-K proteins were found to stimulate the growth of these tumours, and targeted drugs have been identified to reduce their growth.
Researchers at the University of Plymouth have discovered a biomarker, Fibulin-2 (FBLN2), that can distinguish between grade I and II meningioma tumours. This breakthrough could spare surgery for up to 85% of patients with lower-grade tumours, reducing the need for high-risk treatments.
A large study found that prolonged high dose use of cyproterone acetate increases the risk of developing meningioma, a mostly non-cancerous brain tumour. The risk declines after stopping treatment, suggesting a biologically plausible causal relationship.
Researchers discovered a modified protein in benign-appearing meningiomas that can reveal which are truly benign and which are more dangerous. The finding may inform the discovery of drugs to treat these tumors more effectively.
Researchers at Baylor College of Medicine developed a reliable molecular profile for meningiomas, predicting tumor recurrence with high accuracy. The study identified a unique characteristic of aggressive meningiomas, the dysfunction of the DREAM complex, which contributes to malignant transformation.
Researchers have identified FGFR3 mutations in a subset of meningioma patients with favorable prognoses, suggesting potential for targeted therapy. These mutations may enhance diagnostic accuracy and clinical decision-making.
The INTEROCC study found no clear association between occupational exposure to high-frequency electromagnetic fields and risk of glioma or meningioma. However, the researchers suggest that radiofrequency magnetic fields may be associated with increased tumour promotion, warranting further investigation.
The Synodos for NF2 consortium published its first set of results, showing that drug combination therapies are effective in treating schwannomas and meningiomas. The team integrated innovative research approaches to analyze gene and protein expression, finding that different drugs are likely needed to treat these two tumor types.
Researchers identified genetic mutations that distinguish aggressive rhabdoid meningiomas from benign forms, suggesting a potential new approach for clinical decision-making. The study found patients with BAP1 mutations had poor clinical outcomes and shorter disease progression times.
Researchers at Ohio State University have found that high blood sugar is associated with a lower risk of developing meningiomas, a type of benign brain tumor. Women with the highest fasting blood sugar levels were less than half as likely to develop a tumor.
The EORTC 1320 trial, coordinated by the EORTC Brain Tumor Group, aims to assess the efficacy and safety of YONDELIS (trabectedin) compared to standard care in patients with recurrent grade II or III meningioma. The study plans to accrue 86 patients across 47 sites in ten countries.
A new meta-analysis found that being overweight or obese increases the risk of meningioma by 21% and 54%, respectively. Conversely, high physical activity was associated with a decreased risk of meningioma.
A novel radioguided surgery technique using Y-90 DOTATOC can effectively identify residual cancer cells during brain tumor surgery, reducing healthy tissue removal. The study's findings suggest the potential for improved resection margins and enhanced patient outcomes.
A survey of female meningioma survivors aged 25-44 found they were more likely to want and intend to have a child than the general population, driven by concerns over recurrent meningioma and treatment needs. Physicians' advice on risk factors also influenced their decisions.
A Loyola University Medical Center study has found radiation to be a risk factor for the development of meningiomas, a type of brain tumor, in individuals under age 30. The study analyzed records of patients diagnosed with meningiomas before age 30 and found that five had been exposed to ionizing radiation earlier in their lives.
Researchers found NY-ESO-1 protein in nearly all high-grade meningiomas, a potential new target for therapies. The protein is already being tested in a clinical trial at the National Cancer Institute.
A new gene, SMARCE1, has been identified as responsible for causing spinal meningioma, an inherited form of tumor. The discovery was made using next-generation sequencing technology and could lead to better testing, treatment, and care for patients.
A team of researchers at Yale University has identified four new genetic suspects linked to the origins and treatment of meningiomas. The study found that tumors mutated with these genes tend to be located in different areas of the brain, indicating their likelihood of becoming malignant.
Large-scale genomic sequencing reveals two DNA mutations driving 15% of meningiomas, a type of slow-growing brain tumor. The findings suggest targeted therapies may provide an effective treatment option for these patients.
A new study found that rapid tumor growth in pregnant women with meningiomas is linked to blood flow changes, not hormonal fluctuations. Most of the tumors showed an unusual 'hypervascular' pattern and high edema rates.
Johns Hopkins researchers discovered a cellular mechanism driving meningioma growth and progression. The study identified the activation of YAP1 protein in nuclei as a crucial step in tumorigenesis, suggesting new treatment targets.
A study published in Cancer found that frequent dental x-rays are linked to an increased risk of developing meningioma, the most commonly diagnosed primary brain tumor in the US. Patients who received bitewing exams or panorex exams on a yearly or more frequent basis were at higher risk of developing meningioma.
Research finds frequent dental X-rays in childhood and young adulthood may increase risk of developing meningioma. Patients who had yearly or more frequent bitewing exams were 1.4-1.9 times more likely to develop meningioma compared to controls.
Researchers at Thomas Jefferson University found that fractionated stereotactic radiotherapy is effective in controlling optic nerve sheath meningioma growth while preserving vision. The treatment resulted in a high rate of stabilized or improved visual acuity, with minimal late complications.
Patients with rare brain tumors may have a genetic predisposition to develop the condition. Radiation exposure increases the risk of developing these tumors in families where multiple members are exposed.
Researchers at Thomas Jefferson University found that COX-2 expression is higher than normal in meningioma and pituitary macroadenomas, with more aggressive disease associated with greater enzyme presence. The study opens up opportunities for designing potential therapies against brain tumors.
Researchers develop mouse model of sporadic and familial human meningioma, demonstrating NF2 loss is sufficient for tumor formation. The study provides novel insight into the role of the NF2 gene in meningioma development and enables testing of potential therapies.
Researchers at NHLBI discovered that women with LAM have a high rate of meningiomas, a surprising finding that has implications for diagnosis and treatment. The study suggests using MRI scans to screen for tumors and avoiding progesterone in affected patients.